Anagliptin a DPP4 Inhibitor Slightly Suppresses Glucagon as Measured by LCHRMS
*Corresponding Author:
Copyright: © 2021 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The etiology and pathology of type 2 diabetes are insufficient insulin action, which involves an increase in insulin resistance due to environmental factors and/or a decrease in insulin secretion mainly due to genetic factors. Glucagon is secreted from alpha cells of the pancreas as a hormone that antagonizes the action of insulin. Abnormal glucagon secretion is also thought to be a factor in raising blood glucose levels. In normal glucose tolerance, when insulin secretion from β cells increases in response to an increase in blood glucose level, the insulin suppresses glucagon secretion from α cells in paracrine manner.
